Verapamil calcium channel blockers

Description Results NMA

all cause death NaN [NaN; NaN]

confirmed myocardial infarction 1.00 [1.00; 1.00]

all cause death 0.00 [0.00; NaN]

confirmed myocardial infarction 1.00 [1.00; 1.00]

all cause death 0.82 [0.63; 1.05]

cardiac death 0.80 [0.61; 1.05]

all cause death 1.06 [0.64; 1.73]

cardiac death 0.97 [0.54; 1.75]

reinfarction 0.81 [0.54; 1.22]

confirmed myocardial infarction 0.99 [0.92; 1.07]

Verapamil 5 to 10 mg/h IV (n=29)

vs.

no treatment (n=25)

open

Parallel groups

Sample size: 29/25

Primary endpoint: infract size

FU duration: 2 days

verapamil 120mgx3 (n=1751)

vs.

placebo (n=1747)

Double blind

Parallel groups

Sample size: 1751/1747

Primary endpoint: all-cause mortality

FU duration: 6 months

verapamil 80mgx3 (n=8)

vs.

placebo (n=9)

single blind

Parallel groups

Sample size: 8/9

Primary endpoint: angina and reinfarction

FU duration: 10 days

verapamil 120mgx3 for 18 months (n=878)

vs.

placebo (n=897)

Double blind

Parallel groups

Sample size: 878/897

Primary endpoint: all-cause mortality and firstmajor event

FU duration: 16 months

verapamil retard 360 mg daily (n=531)

vs.

placebo (n=542)

Double blind

Parallel groups

Sample size: 531/542

Primary endpoint: all-cause mortality

FU duration: 23.5 months

verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729)

vs.

placebo (n=1718)

double blind

Parallel groups

Sample size: 1729/1718

Primary endpoint: mortality

FU duration: 12 months

all cause death 0.98 [0.90; 1.07]

non fatal stroke 0.89 [0.70; 1.12]

non fatal MI 0.99 [0.79; 1.24]

verapamil sustained release 240mg/d (n=11267)

vs.

atenolol 50mg/d (n=11309)

Sample size: 11267/11309

Primary endpoint:

FU duration: 2.7 y

all cause death 1.07 [0.92; 1.25]

coronary heart disease 0.81 [0.65; 1.02]

cardiovascular death 1.08 [0.86; 1.35]

stroke (fatal & non fatal) 0.81 [0.65; 1.02]

Major cardiovascular events 1.01 [0.88; 1.17]

controlled-onset extendedrelease(COER) verapamil 180mg/d (n=8241)

vs.

hydrochlorothiazide 12.5 mg/d or atenolol 50 mg/d(investigator choice prior to randomization) (n=8361)

Double blind

Parallel groups

Sample size: 8241/8361

Primary endpoint:

FU duration: 3 y

all cause death 1.25 [0.34; 4.64]

coronary heart disease 0.90 [0.37; 2.20]

cardiovascular death 1.25 [0.34; 4.64]

fatal MI 0.75 [0.17; 3.34]

heart failure ∞ [NaN; ∞]

fatal stroke ∞ [NaN; ∞]

non fatal stroke 0.75 [0.17; 3.34]

non fatal MI 1.00 [0.29; 3.44]

stroke (fatal & non fatal) 1.25 [0.34; 4.64]

Major cardiovascular events 1.07 [0.52; 2.20]

verapamil SR 240 mg/d (n=707)

vs.

chlorthalidone 25mg/d (n=707)

Open

Parallel groups

Sample size: 707/707

Primary endpoint: Not given

FU duration: 2 years

restenosis 0.77 [0.59; 1.01]

verapamil (240 mg bid) (n=89)

vs.

placebo (n=83)

double blind

Sample size: 89/83

Primary endpoint:

FU duration: 6 months

all cause death 0.82 [0.63; 1.05]

cardiac death 0.80 [0.61; 1.05]

all cause death 1.06 [0.64; 1.73]

cardiac death 0.97 [0.54; 1.75]

reinfarction 0.81 [0.54; 1.22]

confirmed myocardial infarction 0.99 [0.92; 1.07]

verapamil 120mgx3 (n=1751)

vs.

placebo (n=1747)

Double blind

Parallel groups

Sample size: 1751/1747

Primary endpoint: all-cause mortality

FU duration: 6 months

verapamil 120mgx3 for 18 months (n=878)

vs.

placebo (n=897)

Double blind

Parallel groups

Sample size: 878/897

Primary endpoint: all-cause mortality and firstmajor event

FU duration: 16 months

verapamil retard 360 mg daily (n=531)

vs.

placebo (n=542)

Double blind

Parallel groups

Sample size: 531/542

Primary endpoint: all-cause mortality

FU duration: 23.5 months

verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729)

vs.

placebo (n=1718)

double blind

Parallel groups

Sample size: 1729/1718

Primary endpoint: mortality

FU duration: 12 months